Podcasts about pharmaceuticals

It has been an eventful summer for 340B, and we are checking in this week with 340B Health President and CEO Maureen Testoni to hear her analysis on the top 340B developments. Maureen provides updates on issues that include the contract pharmacy dispute, Medicare payment cuts, and the new drug pricing law. She also shares a preview of what may occur in the fall. 340B Contract Pharmacy Dispute Continues The number of companies currently restricting 340B discounts has grown. Maureen discusses the impact of these unlawful restrictions on 340B hospitals and patient care, how Congress is responding to advocacy efforts, and where the issue stands in the courts. She also explains how 340B Health is taking a multi-pronged approach to address the dispute. Progress Toward Ending Medicare Cuts The U.S. Supreme Court decided in June that Medicare cuts for 340B drugs that have been in place since 2018 are unlawful. Maureen recaps how the Centers for Medicare & Medicaid Services (CMS) has responded to the court's decision and predicts when hospitals might expect to be repaid for the cuts they received.  New Drug Pricing Law Major federal drug pricing legislation became law in August, and the new law will have significant ramifications that are difficult to predict. Maureen describes the key drug pricing provisions and what they could mean for 340B.Celebrating 340B's Big Upcoming Anniversary Maureen shares her key takeaways from the 340B Coalition Summer Conference. Amid the challenges covered entities face, she believes it is important to recognize the 30th anniversary of the 340B program in November by celebrating the difference 340B has made in patients' lives. Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you'd like us to cover in this podcast, email us at podcast@340bhealth.org. Resources  Survey Results: Contract Pharmacy Restrictions Represent Growing Threat to 340B Hospitals and Patients  Hospitals Say Medicare Must End 340B Cuts, Repay Harmed Facilities Research Shows 340B Meeting Its Mission Maureen Testoni's 340B Coalition Summer Conference 2022 Recap Blog Post Upcoming 340B Health Webinars 

LabOps is the most critical piece at Odin Pharma. In this episode, Mandar Shah, Vice President of Research and Development at Odin Pharma, talks about how his team's operations at the lab, develop improved sterile products with technology. His career evolved from developing new drugs and surgical products to evergreening patents with his R&D at Odin. He details the development process that passes through the formulation and the analytical labs as a group effort where integrity is crucial. He also explains how technology can supplement the LabOps people's work while emphasizing the importance of the human team. He encourages LabOps people to think about what they are doing and why not be monotonous and mechanical. Tune in to this episode to learn how LabOps is crucial for developing sterile products at Odin Pharma! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Hi everyone and welcome to episode #12 of Slice of Life Sciences. We have a great conversation lined up today as we are joined by Chris Bahl, Chief Scientific Officer and Co-Founder of AI Proteins. I have gotten to know Chris this past year, which makes me especially excited to hear about his journey and how it led to this newly founded biotech company focused on the design and engineering of synthetic miniprotein therapeutics.In this episode you'll learn about:  Bahl's background & what made him want to study protein How AI Proteins came about The challenges AI Proteins is solving  The culture of AI Proteins Milestones they are looking to hit What Bahl is most excited about for the future of AI Proteins Advice he would give to aspiring entrepreneurs For more information on AI Proteins please follow these links:- Website - LinkedInThis podcast is produced by Slice of Media, INC.

Bill Taranto is President of the Global Health Innovation Fund at Merck (https://www.merckghifund.com/taranto.html) and founding partner since inception in 2010. Merck Global Health Innovation Fund (Merck GHI) is a corporate venture capital group utilizing a healthcare ecosystem strategy, investing globally in platform companies with proven technologies or business models where Merck's expertise can accelerate revenue growth and enhance value creation to ultimately develop integrated healthcare solutions. Merck GHI has $500M under management per an evergreen model and invests broadly in the domain of digital health, and other segments, and has made over 60 investments in portfolio companies, and has over 20 exits. They invest across the segments of Therapy Planning, Care Management, Health Analytics & AI, eClinical Trials and enabling technologies. Bill has more than 30 years of health care experience including over 20 years of healthcare investing. In addition to his experience in venture investing, Bill has more than a decade of management operations experience. Bill is also the chairman of the Merck Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also Chairman of the GHI Fund LLC Management Board. Prior to joining Merck, Bill spent 18 years at Johnson & Johnson in various venture capital, marketing, sales and business development roles. Before J&J, Bill spent eight years in investment banking. He has a Bachelor of Business Administration from St. Bonaventure University.The Fren ZoneThe Fren Zone brings you the brightest technical minds in crypto and Web3. Join our...Listen on: Apple Podcasts Spotify Discovery MattersA collection of stories and insights on matters of discovery that advance life...Listen on: Apple Podcasts Spotify Fit, Healthy & Happy Podcast Welcome to the Fit, Healthy and Happy Podcast hosted by Josh and Kyle from Colossus...Listen on: Apple Podcasts Spotify

“What is the best diet for PCOS?” Is Paleo the best diet for PCOS? How about Low Carb? Keto? Vegan? Weight Watchers? Raw?” PCOS is not an issue that can't be solved by medication. Pharmaceuticals like metformin and the Pill can't address root causes, but what you eat (and don't eat) can. Eating the right types of food at the right times each month helps rebalance your reproductive hormones, stabilize insulin and blood sugar, and support your unique female biochemistry during each phase of your monthly menstrual cycle.On today's episode, Cody shares everything we need to know about how we can use food to manage PCOS successfully. She answers the questions so many of us have about what foods  we should avoid and which foods we should focus on getting plenty of. What is the perfect diet for PCOS? Tune in and find out!Episode referenced in todays episode: Episode 94: "The Four Types of PCOS"Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also leave us a rating and review on iTunes.Want to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Join Mixhers email list and be the first to have access to new products and be the girl in the know! Be sure to join our movement by following us on Instagram @mixhersorCody Sanders @codyjeansandersJess Toolson @jesstoolsonTo submit questions or if you think you'd be a perfect guest to have on our podcast reach out to us on speakpipe and record your questions for us!

In this episode, Lindy Hughson, Managing Editor & Publisher of PKN Packaging News, talks with Carol Kilcullen-Lawrence, Sustainability Consultant to UPM Raflatac, and Nicholas Rodgers, Packaging Technologist at Ego Pharmaceuticals The podcast explores how the industry is tackling climate change, and its response to the Climate Bill legislative requirements. We get an insight into how UTM Raflatac and Ego are undertaking these positive climate action initiatives ahead of targets, fulfilling consumer expectations, and how they meet label regulatory requirements, through their Forest Film solution, We also get an insight into the relationship between suppliers and brand owners to implement Forest Film and how it won them a number of Packaging Innovation and Design Awards (PIDA) awards. Find out more information about UPM Raflatac's positive climate action at: https://www.upmraflatac.com/sustainable-packaging/our-sustainability-commitments/positive-climate-action/ (www.upmraflatac.com/sustainable-packaging/our-sustainability-commitments/positive-climate-action/) LINKS: Ego Pharmaceuticals - Sustainability ethos etched into packaging design https://www.packagingnews.com.au/latest/sustainability-ethos-etched-into-packaging-design (www.packagingnews.com.au/latest/sustainability-ethos-etched-into-packaging-design) -PIDA awards- Carols 2022 PIDA award - Packaging Industry Professional of the year: http://www.packagingnews.com.au/latest/pida-2022-packaging-industry-professional-of-the-year (www.packagingnews.com.au/latest/pida-2022-packaging-industry-professional-of-the-year) Ego Pharmaceuticals PIDA award - Recycled Content, Marketing Design, and Health, Beauty & Wellness Packaging: https://www.packagingnews.com.au/sustainability/pida-2022-sustainable-packaging-design-of-the-year (www.packagingnews.com.au/sustainability/pida-2022-sustainable-packaging-design-of-the-year)   https://www.packagingnews.com.au/design/pida-2022-marketing-design-of-the-year-award (www.packagingnews.com.au/design/pida-2022-marketing-design-of-the-year-award) https://www.packagingnews.com.au/markets/health-and-beauty/pida-2022-health-beauty-and-wellness-packaging (www.packagingnews.com.au/markets/health-and-beauty/pida-2022-health-beauty-and-wellness-packaging) ------------------------------ The PKN Podcast is produced by Southern Skies Media on behalf of PKN Packaging News, owned and published by Yaffa Media. The views of the people featured on this podcast do not necessarily represent the views of PKN Packaging News, Yaffa Media, or the guest's employer. The contents are copyright by Yaffa Media. If you wish to use any of this podcast's audio, please contact PKN Packaging News via their website www.packagingnews.com.au or send an email to editor@packagingnews.com.au. MC: Grant McHerron Host: Lindy Hughson Producer: Steve Visscher PKN Packaging News - © 2022

“If Germany goes recreational,  everybody's going to follow them to some extent. If the leader says, look, this is how I'm addressing the product, the issue that I see at hand, you can pretty much be sure all the bigger countries will come in line like France, Portugal… And a few others are going to really move quickly because there's no reason for them to be disadvantaged if the rules are already set.” - Michael SassanoWelcome back to the To Be Blunt podcast! In this episode, Shayda Torabi welcomes Michael Sassano of SOMAI Pharmaceuticals to take a broader look at the global cannabis market. He brings his wealth of experience to dive deep into European cannabis production, innovation, and legalization and juxtaposes the current landscape with what's happening in North America. He also talks about SOMAI and how they are producing high-quality medical cannabis treatments for patients all over the world. [00:00 - 09:05] Thoughts on My Germany Trip[09:06- 21:10] Europe's Leading Cannabis Markets[21:11 - 37:04] Regularization and Comparing Recreational vs. Medicinal[37:05 - 46:52] The Pharmaceutical Industry and Innovation[46:53 - 53:42] Marketing Cannabis to European Consumers[53:43 - 1:03:41] What It Takes to Be Licensed and to Operate in Europe[1:03:42 - 1:14:40] A Look at the US Market and The Future of SOMAI Michael is the CEO and Chairman of the Board for SOMAI Pharmaceuticals LTD, a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal, and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. SOMAI emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Taking with him the product development knowledge honed in the competitive American market, SOMAI is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's.Connect with Michael!Check out somaipharma.eu! Watch this episode on YouTube:https://www.youtube.com/watch?v=66yTNFlh20MShayda Torabi has been called one of the most influential Women in WordPress and now she's one of the women leading the cannabis reformation conversation building one of Texas' premier CBD brands. She's currently the CEO and Co-Founder of RESTART CBD, a female-run education first CBD wellness brand. And has formerly held marketing positions at WP Engine and WebDevStudios. Shayda is the host of a podcast for cannabis marketers called To Be Blunt, where she interviews top cannabis brands on their most successful marketing initiatives. When Shayda's not building her cannabiz in Texas, you can find her on the road exploring the best hikes and spots for vegan ice cream. Follow Shayda at @theshaydatorabi SPONSORSHIP is brought to you by Restart CBD. Check them out for your CBD needsLEAVE A REVIEW + help someone who wants to join me for episodes featuring some serious cannabis industry by sharing this episode or click here to listen to past episodesRESTART CBD is an education-first CBD wellness brand shipping nationwide.RESTART CBD RESTART CBD is an education first CBD wellness brand shipping nationwide. restartcbd.com

There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.

Neuren Pharmaceuticals CEO Jon Pilcher speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological disorders that emerge in childhood. The company has two drugs in clinical development for multiple serious neurological diseases for which there are currently no approved drug therapies. #NeurenPharmaceuticals #drugtherapy #neurologicaldisorders #asx #proactiveaustralia

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted permission to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 or DMT for the treatment of stroke. The study will be conducted in the Netherlands at the Centre for Human Drug Research in Leiden. The screening for patients is expected to begin in Q4 or this year. The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous.

Drug shortages occurring throughout the U.S. health system can lead to delays for patients receiving the medications they need. 340B hospitals face unique challenges with avoiding and managing drug shortages. We are joined by Cescilly Smith-Jenkins, 340B program director at Ascension Wisconsin, to find out how 340B hospitals can address shortage problems effectively. Why Drug Shortages HappenThere are several factors behind drug shortages. Cescilly explains how drug shortages are affected by other supply shortages, outlines drug shortage trends in the U.S., and notes which drugs are most prone to being in short supply.340B Challenges to Managing Shortages 340B compliance adds additional complexity to drug shortages. Cescilly discusses how regulatory policies create challenges for avoiding shortages on 340B-eligible drugs. She also shares an example of how her health system overcame a recent drug shortage.   Approaches to Stay Ahead of Shortages  Cescilly has a unique way to think about 340B that can help hospitals operate their program in a way that stays ahead of drug shortages. She also explains risks that can occur when the 340B team is unaware of hospital operational changes, and she provides practical tips on maintaining communications with key stakeholders. Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you'd like us to cover in this podcast, email us at podcast@340bhealth.org.Resources Annual Hospital Recertification Closes Sept. 19  340B Insight Episode 55: Are You Ready for 340B Recertification?

Welcome to the LabOps Leadership Podcast! In this episode, Karen Correa, Vice President and Head of Global Clinical Operations at Takeda, talks about her overseeing global clinical operations and trials across multiple therapeutic areas. She discusses putting the patient first by focusing on developing decentralized clinical trials, increasing diversity, mitigating risks, and cross-pollinating with other companies and industries. She shares her thoughts on learning how to be a leader and finding the proper message delivery to reach your audience. Karen points out the importance of collaboration and making an impact by helping others. Tune in to this episode to learn how the work Karen Correa does at Takeda is making a difference in LabOps! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Thanks everybody for joining us on episode #11 of Slice of Life Sciences.I'm very much looking forward to today's episode as I am joined by Jake Lombardo, Co-Founder and CEO at Anodyne Nanotech, which is a venture-backed, preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs.In this episode you'll learn about:  Lombardo's background Where he grew up, and how he gained interest in biotech His mentors that inspired him early on   His time at Union College, and his research projects there His time at Tufts University's Gordon Institute to receive a Master of Science in Innovation and Management The founding of Anodyne Nanotech the genesis of the company The problem the Anodyne team is solving and what applications on the world their science/technology can have The Hero Patch Pharmaceutical partners that Anodyne is working with The seed round received last AprilWhat this means for the growth of Anodyne, and what the investment been put towards  The challenges Lombardo has faced with Anodyne Nanotech, and what continues to excite him  How he's juggled hiring, fundraising, and managing a team? and about being an entrepreneur:  Was there a specific moment Lombardo knew he wanted to be an entrepreneur, or did it happen organically? And  any advice he'd give to another ‘Jake Lombardo' getting his master's about to start a company?  Jake, thanks so much for taking the time to chat with us...can't wait to continue hearing about your teams' successes and growth!This podcast is produced by Slice of Media, INC.

In this episode, actor/filmmaker Arnold Chun shares his life journey and how he entered the creative industry. He and Rasha discuss career changes, representation, and the ever-changing media landscape. Arnold was born in Boston, MA and raised in Los Angeles since he was 3. While earning his BA in European/East Asian History at UC Irvine, he worked as a supervisor of Intramural Athletics and formed the UC Irvine men's Volleyball Club in 1997. He then taught English for the Nagano Board of Education in Japan from 1998-1999, working part-time for the local English journal. With the completion of his service in Japan, Arnold found work for a fortune 500 mechanical engineering firm. He was a top consultant before leaving that field to pursue a career in Pharmaceuticals. Arnold volunteered as a Production Assistant for a project for Eric Kim (EKFilms). Within a week, the job led to future opportunities that brought him into a career in acting. Over the years, Arnold has quickly risen to be a top player in the entertainment industry. He has worked with Academy Award Winning director: Clint Eastwood. He has worked with Michael Bay, David Schwimmer, and countless other top directors. In 2007 Arnold stepped into his directorial debut with a short film about life in Koreatown called, "Eli's Liquor Store," It traveled to over 20 Festivals and was distributed by Imaginasian Cable TV. He was nominated for the Melvin Van Peebles Award, won Best Short at Harlem Int. Film Fest, won an award for Excellence in Filmmaking at the Honolulu Film Fest, and was selected to be an opening presenter at the Smithsonian National Martin Luther King Consortium during Black History Month.

Changing the conversation around infused food and cannabis tourism, Jeremy Smith joined Ryan Purvis on the Shake Podcast. Jeremy Smith was a professional bodybuilder before making the pivot into the cannabis industry. Dealing with a host of ailments, Jeremy partnered in Cannabis for relief with Crohn's Disease and to decrease his opioid use. Today, he's moving the needle forward with nutrition, education and a push for cannabis tourism. Jeremy joined Ryan on Episode 02 to take a deep dive into all things Sports Cannabis, his professional cannabis pivot, Cannabis vs Pharmaceuticals, Infused Foods, Les Munchies Inc. - the movement and Canadian Cannabis tourism. Hosted by: Ryan Purvis Powered & Production by Sports Cannabis Inc.

In this episode, DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise.See omnystudio.com/listener for privacy information.

The development of penicillin started – but definitely did not end – with the chance discovery of some mold in a petri dish. There is so much more to the story. Research: Bernard, Diane. “How a miracle drug changed the fight against infection during World War II.” Washington Post. 7/11/2020. https://www.washingtonpost.com/history/2020/07/11/penicillin-coronavirus-florey-wwii-infection/ British Library. “Inventor(s) of the month, Alexander Fleming and the story of Penicillin.” 7/28/2021. https://blogs.bl.uk/business/2021/07/inventors-of-the-month-alexander-fleming.html Chain, E. et al. “Penicillin as a Chemotherapeutic Agent.” The Lancet. Vol. 236, Issue 6104. 8/24/1940. https://doi.org/10.1016/S0140-6736(01)08728-1 Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. Br J Exp Pathol. 1929 Jun;10(3):226–36. PMCID: PMC2048009. Gaynes, Robert. “The Discovery of Penicillin—New Insights After More Than 75 Years of Clinical Use.” Emerg Infect Dis. 2017 May; 23(5): 849–853.. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403050/ Lee, Victoria. “Microbial Transformations.” Historical Studies in the Natural Sciences, SEPTEMBER 2018, Vol. 48, No. 4. Via JSTOR. https://www.jstor.org/stable/10.2307/26507225 National Museums of Scotland. “Culture Vessel.” https://www.nms.ac.uk/explore-our-collections/stories/science-and-technology/culture-vessel/ Quinn, Roswell. “Rethinking Antibiotic Research and Development: World War II and the Penicillin Collaborative.” American Journal of Public Health | March 2013, Vol 103, No. 3. Scibilia, Anthony Julius. “Being Prometheus in 1943:: Bringing Penicillin to the Working Man.” Pennsylvania History: A Journal of Mid-Atlantic Studies , Vol. 80, No. 3 (Summer 2013). https://www.jstor.org/stable/10.5325/pennhistory.80.3.0442 Science History. “Alexander Fleming.” 12/5/2017. https://www.sciencehistory.org/historical-profile/alexander-fleming Science Museum. “How Was Penicillin Developed?” 2/23/2021. https://www.sciencemuseum.org.uk/objects-and-stories/how-was-penicillin-developed Shama, Gilbert. “'Déjà Vu' – The Recycling of Penicillin in Post-liberation Paris.” Pharmacy in History , 2013, Vol. 55, No. 1 (2013). Via JSTOR. https://www.jstor.org/stable/23645718 The Alexander Fleming Laboratory Museum, London, UK. “The Discovery and Development of Penicillin 1928-1945.” 11/19/1999. https://www.acs.org/content/dam/acsorg/education/whatischemistry/landmarks/flemingpenicillin/the-discovery-and-development-of-penicillin-commemorative-booklet.pdf Wainwright, Milton. “Moulds in Folk Medicine.” Folklore , 1989, Vol. 100, No. 2 (1989). https://www.jstor.org/stable/1260294 Wainwright, Milton. “The History of the Therapeutic Use of Crude Penicillin.” Medical History, 1987, 31: 41-50. Williams KJ. The introduction of 'chemotherapy' using arsphenamine - the first magic bullet. J R Soc Med. 2009 Aug;102(8):343-8. doi: 10.1258/jrsm.2009.09k036. PMID: 19679737; PMCID: PMC2726818. Wood, Jonathan. “Penicillin: The Oxford Story.” Oxford News Blog. 7/16/2010. https://www.ox.ac.uk/news/science-blog/penicillin-oxford-story Zaffiri, Lorenzo et al. “History of Antibiotics. From Salvarsan to Cephalosporins.” Journal of Investigative Surgery, 25, 67–77, 2012.  See omnystudio.com/listener for privacy information.

This is a compilation of some of the most compelling stories of the week.See omnystudio.com/listener for privacy information.

Break into Medical Device Sales Online Course: https://courses.newtomedicaldevicesales.com/ref/Drew+Roberts/ Guide For Breaking into Medical Device Sales Ebook: https://newtomedicaldevicesales.squarespace.com/ New to Medical Device Sales Podcast: https://podcasts.apple.com/us/podcast/new-to-medical-device-sales/id1522512043 New to Medical Device Sales YouTube: https://www.youtube.com/channel/UChOykksIXUXAwnW0rq6lKmw Medical Sales Network Effects Program: https://salesnetworkeffectsprogram.mykajabi.com/a/2147517020/JdaoyhuE LinkedIn Profile Upgrade: https://salesnetworkeffectsprogram.mykajabi.com/a/2147515981/JdaoyhuE Website: https://www.newtomedicaldevicesales.com New to Medical Device Sales Instagram - https://www.instagram.com/newtomedicaldevicesales/ Jacob McLaughlin LinkedIn- https://www.linkedin.com/in/jacob-mclaughlin-5192b312b New to Medical Device Sales TikTok: https://www.tiktok.com/@newtomedicaldevicesales? --- Support this podcast: https://anchor.fm/jacob-mclaughlin25/support

New 2022 - Butchered by “Healthcare”: What to Do About Doctors, Big Pharma, and Corrupt Government Ruining Your Health and Medical Care - Robert Yoho, MD  Dr. Robert Yoho • http://www.robertyohoauthor.com • Book - Butchered by “Heathcare” #RobertYoho  #BigPharma #HealthCare #BigGovernement Dr. Robert Yoho is an author and accomplished retired Los Angeles cosmetic surgeon. His Book, Butchered by “Heathcare”: What to Do About Doctors, Big Pharma, and Corrupt Government Ruining Your Health and Medical Care. Healthcare is the top cause of all our overdue debts and personal bankruptcy. Our medical spending per person is double that of other countries', but fully half the treatments are ineffective or harmful. Immense, predatory industries such as angioplasty and coronary artery bypass surgery victimize us. These procedures cause complications and deaths, but few patients survive even a day longer. Most back and endoscopic knee surgeries are equally worthless. Seventy percent of us are on prescriptions, and 20 percent take over five. One in six uses psychiatric medicine, which commonly causes irreversible brain damage and premature death. Millions are now addicted to prescription opioids. Ninety-three thousand people died in 2020 from overdoses. The FDA allows big Pharma to falsify the studies required to patent drugs. These corporations hire armies of ghostwriters to stuff websites and medical journal articles with marketing lies. Finding the truth is now nearly impossible. But all this gets overlooked as the companies pay billions of dollars in criminal settlements nearly every year. Money short-circuits everyone's integrity, but there is an alternative. Patients and doctors can still prevail. Learn the system, and you can too by reading his book Butchered by “Heathcare. Dr Robert Yoho grew up in Kent Ohio. He was an Eagle Scout and a Judo wrestler. Went to Oberlin College and Case Western Reserve Univ. Medical School. In 2019 Dr Yoho retired from his medical and surgical practice. He now is a full time writer and speaker. No longer responsible for patient care he is able to write full time without conflicts of interest. To Contact Dr Robert Yoho go to  robertyohoauthor.com CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:  https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Pharmacy technicians play key roles in hospital 340B program operations, but pharmacy technician staffing shortages are occurring in hospitals throughout the nation. We're joined by Dr. Tyffani Wingfield with the American Society of Health-System Pharmacists (ASHP) to discuss how the shortages are affecting hospitals, the pharmacy technician workforce, and 340B. Tyffani also shares potential solutions. Before the interview, we discuss recently enacted federal drug pricing legislation and the start of the annual 340B hospital recertification process.  Factors Contributing to the Pharmacy Tech ShortagePharmacy technician vacancy rates are high. Tyffani shares results from a pair of ASHP surveys that provide insights into the most prominent challenges hospitals face in recruiting and retaining technicians as well as potential solutions.How Pharmacy Tech Shortages Affect Hospitals  Tyffani explains the vital roles pharmacy technicians fill, the strain on the health care system when there aren't enough technicians, and how hospital organization structures can be modified to support techs. She also provides advice for how pharmacy technicians can have a satisfying career.What the Pharmacy Tech Shortage Means for 340B The staffing shortage has affected technicians operating 340B programs and pharmacy services. Tyffani describes how the staffing shortage affects 340B professionals in their day-to-day work. Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you would like us to cover in this podcast, email us at podcast@340bhealth.org.Resources  Medicare Drug Price Negotiation Bill Becomes Law  340B Health Webinar: Inflation Reduction Act Drug Pricing Provisions and 340B  340B Insight Episode 55: Are You Ready for 340B Recertification? ASHP's Executive Summary for the Pharmacy Technician Shortage Survey Findings 

PolicyWTF: Revdi Fertiliser CultureThis section looks at egregious public policies. Policies that make you go: WTF, Did that really happen? - Pranay KotasthaneIn the past, we have discussed many government plans of the “One Nation, One X” kind. Still, I must confess. Of all things that can substitute the letter X, “fertiliser” was beyond my thinking horizon. Limited thinking wasn’t a problem for the government, which has:“decided to implement One Nation One Fertiliser by introducing single brand name and the logo under fertiliser subsidy scheme namely Pradhan Mantri Bhartiya Janurvarak Pariyojana (PMBJP).”While you decipher what this order means, a short detour about the abbreviation PMBJP is in order. Its usage suggests something profound — the government is finally running out of acronyms! I claim so because there’s an existing scheme with the same abbreviation in the very same ministry — the older Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), run by the Department of Pharmaceuticals since 2008. Perhaps the reason for repeating this abbreviation is apparent — it comprises both the ruling party and the party leader. To make matters more confusing, this scheme has been hailed as “the call of #NewIndia which will take our nation to greater heights” by a politician whose name also abbreviates to BJP.The new PMBJP seems utterly bizarre at first. Why would the government want all companies—government-run or private—to sell their products under a single brand name of ‘Bharat’? Why would a government order go to such lengths to specify that “Two-thirds of the area on the top half of a fertiliser bag will be used for the official branding and logo of the PMBJP while a fertiliser firm can use the rest one-third area for its own logo and branding as well as printing other information relating to the product”?If you dig deeper, the bizarreness gets replaced by a sense of rejection. The diktat to dissolve the value of all fertiliser brands only takes the veneer off the sham called a market for fertilisers. Here’s how.The fertiliser sector is insanely regulated even by Indian standards. It all began with good intentions. One of the components of the Green Revolution was to subsidise agricultural inputs. And so, a fertiliser subsidy was introduced. The government fixed the retail price of urea fertiliser considerably below the market price to encourage its usage. This difference between the market and administered prices was called “fertiliser subsidy”. The government paid off the difference to fertiliser companies with taxpayers’ money. Simultaneously, the government started running fertiliser plants to increase supply. Combined with the Minimum Support Price (MSP) mechanism guaranteeing procurement of certain grains, these measures worked to the extent that Punjab, Haryana, and a handful of other states were able to increase grain production rapidly. The fears of India’s dangerous “population bomb” subsided. But as you might anticipate, interfering with prices had unintended consequences. An overuse of subsidised fertilisers led to a decline in soil quality. An artificially low price also led to the diversion of urea for non-agricultural uses. Urea is a versatile material used in textiles, paint, explosives, and medicinal sectors. Naturally, people purchased cheap fertilisers from retail shops and diverted them to these industries. The government then introduced the Fertiliser (Movement Control) Order, 1973. Fertiliser couldn’t be sold across states within India without the ministry's permission. Instead, state-level fertiliser requirements were aggregated at the union ministry level, and each state had its quota “allocated” from in-state and select out-of-state fertiliser manufacturing facilities. And, of course, there were the usual export restrictions until recently. Essentially, there’s no such thing as a market for fertilisers. Just as MSP effectively turned farmers into government employees, the fertiliser subsidy turned manufacturers into satellite government agencies meant for supplying fertilisers. Meanwhile, the fertiliser subsidy bill kept rising. It is now the union government’s second-largest explicit subsidy, behind only food. For reference, India spent more on fertiliser subsidy last year than it did on defence capital expenditure. This year, higher international prices due to the Ukraine war mean that the government’s fertiliser subsidy bill will shoot up further. And so, the government decided: if we’re going to pay Rs 2 lakh crore to our fertiliser contractors (companies) annually, why not claim the full credit for it? And that’s how we got the One Nation, One Fertiliser scheme. While the name might seem bizarre, it is just the high point of continued government interference in this sector.We can anticipate the unintended consequences. Fertiliser companies—now unable to differentiate their products—will be further disincentivised from improving or innovating. With the PMBJP branding at the front and centre of every fertiliser bag, the endowment effect of the subsidy will grow stronger. It’s now explicit that the government supplies fertilisers to farmers, not companies. Which government will now take the risk of being seen as anti-farmer by reducing this subsidy bill?A better alternative would’ve been to eliminate all complex controls over the fertiliser sector and increase the amount provided as income support to farmers under the PM-KISAN scheme instead. A subsidy to fertiliser manufacturers made sense in the 1960s due to food shortage. It continued to make some sense until there was no way to identify farmers. But now, with an income support scheme already identifying farmers via Aadhaar, it is unconscionable to direct taxpayer money for another subsidy programme. We are stuck in a low-level equilibrium that just keeps getting worse.Global Policy Watch #1: Karza Maaf KaroGlobal issues and their implications for India— RSJThe wonderful thing about bad ideas is how so many politicians find them good. Good ideas must go through the steeplechase of policy proposals, committees and reports. Then they run the marathon to solicit bipartisan political support and public acceptance. And, if they are lucky, they make the finish line alive. No such test of endurance for bad ideas. They fly past these hurdles flipping the bird to them. Time and place don’t matter. Bad ideas are welcome. Everything, everywhere, all at once. The immediate cause for that short ode to bad ideas is the announcement by the Biden administration this week of a student loan forgiveness programme. If you missed the news, here’s a summary from New York Times:“President Biden announced a plan on Wednesday to wipe out significant amounts of student loan debt for tens of millions of Americans, saying he would cancel $10,000 in debt for those earning less than $125,000 per year and $20,000 for those who had received Pell grants for low-income families.Students who received Pell grants will be eligible for $20,000 in debt forgiveness on their loans. About 60 percent of borrowers have received Pell grants, and the majority come from families making less than $30,000 a year. The Education Department estimates that 27 million borrowers will qualify for up to $20,000 in relief.Millions of other borrowers will be eligible for $10,000 in debt relief, as long as they earn less than $125,000 a year or are in households earning less than $250,000.”Good IntentionsWhat will this cost the exchequer? There is a wonderful report on this by the Penn Wharton Budget Model team at the University of Pennsylvania. It has a detailed analysis of the impact of the announcement. I will leave you with the summary:“President Biden’s new student loan forgiveness plan includes three major components. We estimate that debt cancellation alone will cost up to $519 billion, with about 75% of the benefit accruing to households making $88,000 or less. Loan forbearance will cost another $16 billion. The new income-driven repayment (IDR) program would cost another $70 billion, increasing the total plan cost to $605 billion under strict “static” assumptions. However, depending on future IDR program details to be released and potential behavioral (i.e., “non-static”) changes, total plan costs could exceed $1 trillion.”All right. $605 billion under static assumptions and $1 trillion based on future behaviour changes. I will bet this will easily go north of that number because such announcements change the credit culture of a society. We, Indians, know it. So, apart from the $1.9 trillion that Biden announced early last year as part of the COVID-19 relief and build back better package, we have another trillion of stimulus being given back to largely the top two quintiles of the US households. A trillion here, a trillion there, and pretty soon we are talking about real money, to misquote that famous quip by Senator Dirksen. Of course, there are these pious reasons for this policy from the White House press release:“Since 1980, the total cost of both four-year public and four-year private college has nearly tripled, even after accounting for inflation. Federal support has not kept up: Pell Grants once covered nearly 80 percent of the cost of a four-year public college degree for students from working families, but now only cover a third. According to a Department of Education analysis, the typical undergraduate student with loans now graduates with nearly $25,000 in debt.The skyrocketing cumulative federal student loan debt—$1.6 trillion and rising for more than 45 million borrowers—is a significant burden on America’s middle class. Middle-class borrowers struggle with high monthly payments and ballooning balances that make it harder for them to build wealth, like buying homes, putting away money for retirement, and starting small businesses.For the most vulnerable borrowers, the effects of debt are even more crushing. Nearly one-third of borrowers have debt but no degree…”A college education is a passport to higher income and better life in the US. It is the single most significant determinant of social mobility. Two data points from this Pew report puts this in context. First, in 2021, full-time workers ages 22 to 27 who held a bachelor’s degree, but no further education, made a median annual wage of $52,000, compared with $30,000 for full-time workers of the same age with a high school diploma and no degree. Second, households headed by a first-generation college graduate – that is, someone who has completed at least a bachelor’s degree but does not have a parent with a college degree – had a median annual income of $99,600 in 2019, compared with $135,800 for households headed by those with at least one parent who graduated from college. The median wealth of households headed by first-generation college graduates ($152,000) also trailed that of households headed by someone with a parent who graduated from college ($244,500).A college education helps you earn more. And if you have two generations of college education in your family, you’re made. This should be a sufficient incentive for people to take the risk of a college loan and graduate because it does make a difference. Also, the so-called debt burden as a percentage of income is disproportionately high among people who take student loans but don’t graduate. About 40 per cent of students who take loans never graduate. They find it difficult to shrug off the burden throughout their lives. Unintended Consequences When you look at the data together, you should reach the following conclusions:A college education is an expensive affair in the US. The universities have gotten richer over the years, with their trust funds rivalling many private fund houses. The universities seem to have kept the supply limited. The demand has kept soaring, and the somewhat easy availability of credit has meant college fees have grown faster than inflation. The nature of regulations and a stranglehold on accreditation by universities have meant no meaningful disruption in the college education space. A few attempts were made during the pandemic with digital courses, unbundling of the university stack and income share agreement models of funding college education, but they seem to have lost steam once the world got back to normalcy. The universities can continue to retain their oligopoly and set their own prices without real fear of disruption.Then there is a question of alignment of incentives between the borrower and the lender. A college education is the most critical factor for higher income in US society. For the average student, the risk of taking a loan is worth it. Also, taking a loan and not completing college has terrible consequences. This is not some kind of design flaw that’s increasing inequity. It is how it should be. Lastly, the US university system is the best in the world for a reason. It is difficult to get in. You pay a premium for the degree, that money allows the universities to hire and retain faculty who then tend to be of high quality, and it funds research that pushes the boundary of human knowledge. The debt forgiveness program of the Biden administration doesn’t solve the fundamental issue of high college fees. Neither does it strengthen the alignment of incentives between the lender and borrower. In fact, an announcement like this will possibly spur more college applications in future in anticipation of future relief packages like this. That will raise the demand for college seats and increase tuition fees further. Worse, as many have already pointed out, such relief packages have a moral hazard built in. We have written about this in the context of farm loan waivers in India. There are two problems here. When you waive the loans, what do you tell those repaying their debts regularly at great costs to themselves? That they were stupid to do so? Secondly, you have set a precedent for future packages like this. Once that mindset sets in, more borrowers will be taking loans and defaulting because they know the government will bail them out. Mihir Sharma has drawn exactly this parallel with the Indian case in his Bloomberg column this week. He writes:“But the consequence of loan waivers, as they are called in India, have not been at all positive for farmers. Economists have noted that the waivers have encouraged farmers to take on more credit than is justified by their productivity, saddling them with more debt. This cycle of forgiveness and indebtedness reduces the overall flow of agricultural credit, while privileging the minority of borrowers willing and able to game the system. Over the years, multiple cycles of debt forgiveness have not improved household savings, investment or credit flow.…In other words, once you announce a loan waiver program, the incentives of borrowers and politicians change to make both future defaults and future forgiveness more likely. In the US, it’s entirely likely that future administrations will succumb to demands to extend bailouts to those with private loans, for example, or to raise the cap to something more like $50,000 per person.”The other problem is inflation. The consequences of mindless packages since the beginning of the pandemic are there for all to see. The US inflation is at a 40-year high. This relief package will put more money in the hands of the middle class that is already using its excess savings built up during the pandemic to drive up prices. The Fed has been pushing up interest rates to tame inflation. There’s a serious possibility of a recession and debt defaults among the most vulnerable borrowers because of rising rates. More importantly, if the market starts believing that the government doesn’t care about inflation, then high inflation expectations will lead to a real increase in prices. Inflation is expectation driven. It is a self-fulfilling prophecy. That’s why the Fed is careful about its words and why analysts spend so much time parsing its statement. Who in their right mind would want to do this now and set such expectations?The inflation point is particularly important to the rest of the world and to India. Otherwise, who cares what student loan policies are pursued by the Biden administration? Unfortunately, US inflation, interest rates and growth matter to us, as we have already seen in the past few quarters. This bonfire of good economic thinking will singe us. But the persistence and universality of bad ideas cannot be easily fought. There are always short-term reasons to contend with and, of course, elections to be won. Biden’s move is to shore up his popularity among the youth and possibly give Democrats a fighting chance in the mid-terms. These don’t turn out well. But who cares about the future? India Policy Watch: The Elements of Revdi CultureInsights on burning policy issues in India— Pranay KotasthaneThe PM’s revdi culture remark castigating state governments for distributing freebies has been widely debated over the last month. Everyone and their uncles have dipped their toes in the discourse stream. Those on the left have tried hard to prove that freebies are, in fact, desirable social sector spending. Those aligned with the government have highlighted the fiscal imprudence of state governments handing out laptops, TVs, and mixer grinders before elections. My only advice is to read more public finance specialists on this issue and fewer political scientists. What classifies as a subsidy or freebie? Which level of government is guilty of doling out freebies indiscriminately? The discipline of public finance has a lot to offer on such questions. The landmark paper on subsidies in India is by M Govinda Rao and Sudipto Mundle in 1991, in which they devised a subsidy classification. They neatly define a subsidy as:the difference between the cost of delivering various publicly provided goods or services and the recoveries arising from such deliveries.Based on this broad definition, we can classify subsidies along two axes: the nature of the good or service subsidised (merit vs non-merit) and whether they are recognised as subsidies in government accounts (implicit vs explicit). The chart below is my representation of subsidies at the intersection of these two axes.Of the four categories of subsidies, we can now define freebies as non-merit goods which are explicitly or implicitly subsidised by the government. The bone of contention here is the “meritorious” nature of goods. The above paper takes a liberal approach and classifies any good with positive benefits to people beyond the recipient as a merit good.This classification now allows us to understand freebies' volume and nature better. The 1991 paper found that Indian governments were collectively spending almost 15 per cent of GDP on subsidies. Continuing this line of inquiry, Mundle and Sikdar find that the total volume of subsidies had fallen to 10 per cent of GDP by 2015-16. The union government only accounted for 30 per cent of this subsidy bill. State governments accounted for the remaining ~7 per cent of GDP spent on subsidies. Crucially, states subsidised both merit and non-merit goods/services. Since social services like health and education are the primary domain of states according to the constitution, they end up spending ~3 per cent of GDP on such merit goods. The remaining 4 per cent of GDP was spent on non-merit goods. So, the PM’s statement is not incorrect. Both state and union governments have to set their house in order, but on freebies, the state governments have a lot more work to do. The punchline from Sudipto Mundle’s article in Indian Express is vital gyaan for anyone working in Indian public policy:.. four “merit” subsidies account for only a third of total subsidies. Thus, two-thirds of total subsidies, about 6 per cent of GDP, are unwarranted freebies which should be eliminated. .. if central and state governments could step beyond their business as usual budgets and take bold measures to phase out these unwarranted freebies, along with much of the tax exemptions and concessions, which amount to about 5 per cent of GDP, that would free up huge fiscal space. This would enable a massive reduction in the combined fiscal deficit of the Centre and the states, while at the same time stepping up required expenditure on education, health and infrastructure. The myth of restricted fiscal space simply reflects the missing appetite for deep fiscal reforms which could radically change the structure of central and state government finances.”Thanks for reading Anticipating the Unintended! Subscribe for free to receive new posts and support our work.Global Policy Watch #2: Falling In Love With “Your” PoliticianGlobal issues and their implications for India— RSJTaking the cue from the loan forgiveness piece, the question often asked is why do politicians behave the way they do when it is evident that the long-term consequences of their actions will be bad? Like I mentioned a few weeks back, I have been reading an anthology of essays by Bryan Caplan titled - “How Evil Are Politicians?: Essays on Demagoguery”. Caplan introduces the notion of power-hunger in one of the essays and how rational politicians continue to raise it and then try their best to satiate it. Caplan writes:“In Public Choice, also known as “economics of politics,” we usually assume that politicians are motivated not by greed, but by power-hunger.  Of course, we rarely utter the word “power-hunger.”  Instead, we call it “vote maximization,” just as we call greed “profit maximization.”  But when Public Choice pictures politicians, it pictures humans filled with lust for power.Is this a reasonable picture of politicians’ psyches?  Absolutely.  That politicians crave power is as undeniable as that businesspeople crave profits.”Then he argues that democracy and its check and balances might blunt this naked pursuit of power, but that is never enough. He writes:“Under democracy, politicians are less candid about their motives; they need us to like them, and power-hunger is not likeable.  But given its ubiquity throughout most of political history, can we really believe that the motive of power-hunger is no longer paramount? Once you thank the stars you aren’t ruled by Louis XIV or Lenin, a grim truth remains: democracy gives power-hungry politicians far worse incentives than the market gives greedy businesspeople.  Above all, voters – unlike consumers – have no incentive to be rational, spurring power-hungry politicians to preach and practice endless demagoguery.  It’s gotten worse lately, but it’s always been terrible.  Democracy hasn’t turned politicians into decent human beings; it’s only gilded their age-old power lust with altruistic hypocrisy.”So, what’s the solution? Eternal vigilance. And not to be enamoured by any politician and their promises of making your nation great again or reclaiming your deserved vishwaguru status. That’s easier said than done in these days of tribal loyalties and mass disinformation. Bad policies have a lot going for them. HomeWorkReading and listening recommendations on public policy matters[Post] Pakistan is facing a terrible flood event. And the political debate there is not very different from the one we have whenever there's a drought or flood in India. The linked post discusses how causal stories are deployed for telling disparate political stories about such events. [Article] Ritesh Rautela and Anurodh Giri have a good take on India’s fertiliser subsidy program for nextbillion. [1, 2] The two-part article on Subsidies, merit goods, and fiscal space is well worth a read. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit publicpolicy.substack.com

How Big Pharma Broke American Health Care - John Abramson, MD Dr. John Abramson, M.D • https://hcp.hms.harvard.edu/people/john-david-abramson• Book – Sickening #JohnAbramson #BigPharma #AmericanHealthCare #HealthCarePolicy Dr. John Abramson, M.D. is an author and medical doctor and has served as a family physician for over 20 years. His recently release book Sickening  How Big Pharma Broke American Health Care and How We Can Repair It. Is about the inside story of how Big Pharma's relentless pursuit of ever-higher profits corrupts medical knowledge—misleading doctors, misdirecting American health care, and harming our health. The United States spends an excess $1.5 trillion annually on health care compared to other wealthy countries—yet the amount of time that Americans live in good health ranks a lowly 68th in the world. At the heart of the problem is Big Pharma, which funds most clinical trials and therefore controls the research agenda, withholds the real data from those trials as corporate secrets, and shapes most of the information relied upon by health care professionals. In this no-holds-barred exposé, Dr. John Abramson—one of the foremost experts on the drug industry's deceptive tactics—combines patient stories with what he learned during many years of serving as an expert in national drug litigation to reveal the tangled web of financial interests at the heart of the dysfunction in our health-care system. For example, one of pharma's best-kept secrets is that the peer reviewers charged with ensuring the accuracy and completeness of the clinical trial reports published in medical journals do not even have access to complete data and must rely on manufacturer-influenced summaries. Likewise for the experts who write the clinical practice guidelines that define our standards of care. The result of years of research and privileged access to the inner workings of the U.S. medical-industrial complex, Sickening shines a light on the dark underbelly of American health care—and presents a path toward genuine reform. John Abramson MD,  He was twice voted “best doctor” in his area by readers of the local newspapers and three times selected by his peers as one of a handful of best family practitioners in Massachusetts. He has been on the faculty at Harvard Medical School for over 15 years, where he has taught primary care and currently teaches health care policy. He currently consults as an expert in litigation involving the pharmaceutical industry and has served as an unpaid consultant to the FBI and Department of Justice. Dr. Abramson has appeared on more than 65 national television shows, including two appearances on the Today Show, and more recently on the Dr. Oz Show. He was written op-ed pieces in the New York Times LA Times and others. He is the author of the national best-selling book Overdo$ed America.To Contact Dr John Abramson MD, go to https://hcp.hms.harvard.edu/people/john-david-abramson CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

In this flash update, Adam Acosta, Partner, White & Case LLP, provides an overview of recent developments at the FTC on antitrust enforcement in the pharmaceuticals sector. He discusses the FTC's focus on pharmaceutical pricing, developments related to pharmaceutical mergers, and updates related to the FTC's enforcement activity. From AHLA's Antitrust Practice Group.Watch Adam's commentary here.

Corporate Wealth Or Public Health? - Robert Lustig, MD Dr. Robert Lustig • http://www.robertlustig.com • Book - Metabolical #RobertLustig  #BigFood #BigPharma #BigGovernment Dr. Robert Lustig is a The New York Times bestselling author and author of Metabolical: The Lure and the Lies of Processed Food, Nutrition, and Modern Medicine and a Professor of Pediatric Endocrinology at the University of California, San Francisco.  Dr. Robert Lustig, a pediatric neuroendocrinologist who has long been on the cutting edge of medicine and science, challenges our current healthcare paradigm which has gone off the rails under the influence of Big Food, Big Pharma, and Big Government.You can't solve a problem if you don't know what the problem is. One of Lustig's singular gifts as a communicator is his ability to “connect the dots” for the general reader, in order to unpack the scientific data and concepts behind his arguments, as he tells the “real story of food” and “the story of real food.” Metabolical weaves the interconnected strands of nutrition, health/disease, medicine, environment, and society into a completely new fabric by proving on a scientific basis a series of iconoclastic revelations, among them: • Medicine for chronic disease treats symptoms, not the disease itself• You can diagnose your own biochemical profile • Chronic diseases are not "druggable," but they are "foodable" • Processed food isn't just toxic, it's addictive• The war between vegan and keto is a false war—the combatants are on the same side• Big Food, Big Pharma, and Big Government are on the other side Making the case that food is the only lever we have to effect biochemical change to improve our health, Lustig explains what to eat based on two novel criteria: protect the liver, and feed the gut. He insists that if we do not fix our food and change the way we eat, we will continue to court chronic disease, bankrupt healthcare, and threaten the planet. But there is hope: this book explains what's needed to fix all three.Dr. Lustig has become a leading public health authority on the impact sugar has on fueling the diabetes, obesity and metabolic syndrome epidemics, and on addressing changes in the food environment to reverse these chronic diseases. A native of Brooklyn, New York, graduated from Massachusetts Institute of Technology and received his M.D. from Cornell University Medical College. He completed his pediatric residency at St. Louis Children's Hospital, his clinical fellowship at UCSF, his post-doctoral fellow and research associate in neuroendocrinology at The Rockefeller University. He has been a faculty member at the University of Wisconsin-Madison, and the University of Tennessee, Memphis. In 2013, Dr. Lustig received his Masters in the study of Law from University of California, Hastings to enable him to impact the food industry through policy change.Dr. Lustig has authored 125 peer-reviewed articles and 73 reviews. He has mentored 20 pediatric endocrine fellows, and trained numerous other allied health professionals. He provides endocrinologic support to several protocols of the Children's Oncology Group. He is the former Chairman of the Ad hoc Obesity Task Force of the Lawson Wilkins Pediatric Endocrine Society, a member of the Pediatric Obesity Practice Guidelines Subcommittee of The Endocrine Society, a member of the Obesity Task Force of the Endocrine Society, a member of the Pediatric Obesity Devices Committee of the U.S. Food and Drug Administration, a member of the Bay Area Board of Directors of the American Heart Association, and a member of the Steering Committee of Health Foods, Healthy Kids of the Culinary Institute of America. He also consults for several childhood obesity advocacy groups.Dr. Lustig lives in San Francisco with his wife Julie and two daughters. Spare time (what little there is) is spent cooking, theater-going, and traveling.To Contact Dr Robert Lustig, M.D.  go to robertlustig.com CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

On this episode, I interviewed Dr. Anna Arabyan, a faculty member at the USC Leonard Davis School of Gerontology and founder of NutrafemmeRx, a brand devoted to women's hormone health and wellness. I was interested in talking to Dr. Anna because of her unique background in both biochemistry, with her doctor of pharmacy degree, and also using holistic strategies for managing her own diagnoses of PCOS and endometriosis.We had an interesting and wide-ranging discussion touching on everything from the power of community to the shared responsibilities of pharmaceutical companies, doctors, and patients. Take a listen!To connect with Dr. Anna, check out her IG: @nutrafemmerx and her website, https://www.nutrafemmerx.com/

Andrew, Matt and Kev chat through good news on the fusion front, patents and new technology, Thomas Bravo's $1.1b takeover offer for Nearmap (ASX: NEA), Results (Clinuvel Pharmaceuticals (ASX: CUV), Redbubble (ASX: RBL), and Temple & Webster Group (ASX: TPW)), the dangers of extrapolation, and 4DS Memory (ASX: 4DS).Follow us on Twitter: @BabyGiantsPod-----1:00 - Good News - Fusion3:16 - Patents/New Technology4:45 - Nearmap (ASX: NEA) takeover offer from Thomas Bravo16:15 - Clinuvel Pharmaceuticals (ASX: CUV)28:11 - Redbubble (ASX: RBL)36:57 - Temple & Webster Group (ASX: TPW)42:40 - Dangers of extrapolation46:09 - 4DS Memory (ASX: 4DS)48:48 - New tech businesses

Michael chats with David Katz, chief scientific officer and founder of Sparrow Pharmaceuticals. Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams and was a personalized medicine pioneer. He is currently an entrepreneur-in-residence at Oregon Health & Science University. David held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan and earned a B.A. in Chemistry at Pomona College and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University. In this episode, David discusses the creation of Sparrow, the company's work in developing new medicines for patients who have experienced the effects of excess steroids, and how, in his view, developing drugs is just as much of an art as it is a science. This episode is sponsored by Sparrow Pharmaceuticals, sparrowpharma.com.

It's that time of year again to make sure your health system or hospital has everything it needs for the 340B recertification period. 340B Health Vice President of Pharmacy Services Steven Miller returns to the podcast to discuss what is new this year for the recertification process, go over the recertification steps, and provide best practices to recertify without any errors. What's New for Recertification Steve shares the dates that recertification will take place this year and two significant changes from recent years that hospitals need to know. The Recertification ProcessSteve explains the step-by-step process hospitals must go through to confirm and validate the accuracy of their information and submit to the Health Resources & Services Administration. Eligibility Criteria for RecertificationSteve discusses the specific criteria hospitals must meet to qualify for recertification, the importance of the Medicare cost report and the Medicaid Exclusion File for recertification, and when hospitals need to start preparing for recertification. Best Practices and Resources Steve shares common errors, recommendations, and best practices for recertification. He also lists resources 340B Health members can use to prepare for recertification and registration, including 340B Health's upcoming webinar. Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you'd like us to cover in this podcast, email us at podcast@340bhealth.org.Resources  Report: 340B DSH Hospitals Increased Uncompensated Care in 2020 Despite Significant Financial Stress Report: 340B Hospitals Provide Care for High Percentages of Historically Underserved Patients  340B Health Webinars for Members  340B Health 340B Registration and Recertification Resources 

If you are someone that has endured brain injury, loss of optimal function in your cognitive performance, or struggling with your mental health; my guest today has a solution that will help restore your brain function without harmful pharmaceuticals.  Welcome today's guest, Dr. Erik Won, the President of Wave Neuroscience, Inc; a biotechnology company that has innovated a breakthrough technology called Magnetic e-Resonance Therapy (MeRT), which provides solutions for mental disorders like PTSD.This technology utilizes computational neuroanalytics and brain imaging to customize treatment protocols with the aim of restoring optimal neurological function. Dr. Won joined Wave Neuroscience after serving as the Chief Physician and Chief Technology Officer for a Fortune 50 Aerospace company. He also served as a US Navy Flight Surgeon for Marine Medium Helicopter Squadron 268. Dr. Won has been published in numerous peer-reviewed journals and textbooks, and presented in numerous academic conferences.  In this episode we talk about: How this technology helps PTSD, Brain Injury, Depression, Sleep Deprivation, Autism, and other brain damage The importance of sleep and brain health What helps improve your brain health How the beginning of your day prepares you for better sleep and more For full show notes and episode resources head to: https://ericalippy.com/dr-erik-won/ Find our guest at: Dr. Erik Won | Website , Facebook , Instagram  https://waveneuro.com/ Follow me on Social Media: Your Host: @ericalippy Podcast: @passionlovepursuit Facebook YouTube PASSION LOVE PURSUIT PODCASTS: https://ericalippy.com/the-podcast/

Jeff Beck is the Chief Development Officer at BioCareSD, a specialty pharmaceutical distributor. The field of specialty drugs has grown from the first drug for hemophilia in the 1980s to today, with about 50% of the drugs in the pipeline being specialty drugs. BioCareSD is an important component of the supply chain to ensure that these life-saving and life-sustaining drugs are available at the right time and in the right place. Jeff explains, "I'm actually right now at the World Orphan Drug Conference, and it's unbelievable the number of studies that are underway for diseases that maybe a hundred people have, or a thousand people. What we're seeing now is more, and more of these patients are being able to live a really great life, no longer worried about having debilitating conditions. Sometimes, it's life-saving medicine. Sometimes, life-sustaining medicines. At BioCareSD, we're an important cog in the wheel to get those products to the patients." "Specialty pharmaceuticals, it seems like the term has expanded a lot over the days. Sometimes you used to think that specialty pharmaceuticals were just infusible drugs, really high-cost drugs. There are specialty pharmaceuticals now that are pills, but they're unique. They're drugs that usually treat smaller patient populations, so I don't see them moving out of that niche or that term, so to speak." @BioCareSD #BioCareSD #BioCare #SpecialtyDistribution #MedicalSupplyChain #RareDiseases #Pharmaceuticals BioCareSD.com Download the transcript here

Jeff Beck is the Chief Development Officer at BioCareSD, a specialty pharmaceutical distributor. The field of specialty drugs has grown from the first drug for hemophilia in the 1980s to today, with about 50% of the drugs in the pipeline being specialty drugs. BioCareSD is an important component of the supply chain to ensure that these life-saving and life-sustaining drugs are available at the right time and in the right place. Jeff explains, "I'm actually right now at the World Orphan Drug Conference, and it's unbelievable the number of studies that are underway for diseases that maybe a hundred people have, or a thousand people. What we're seeing now is more, and more of these patients are being able to live a really great life, no longer worried about having debilitating conditions. Sometimes, it's life-saving medicine. Sometimes, life-sustaining medicines. At BioCareSD, we're an important cog in the wheel to get those products to the patients." "Specialty pharmaceuticals, it seems like the term has expanded a lot over the days. Sometimes you used to think that specialty pharmaceuticals were just infusible drugs, really high-cost drugs. There are specialty pharmaceuticals now that are pills, but they're unique. They're drugs that usually treat smaller patient populations, so I don't see them moving out of that niche or that term, so to speak." @BioCareSD #BioCareSD #BioCare #SpecialtyDistribution #MedicalSupplyChain #RareDiseases #Pharmaceuticals BioCareSD.com Listen to the podcast here

The guys discuss changes to the breakfast club, deleting Facebook, school daze, plus more. Tap in and hangout with the fellas. Remember to rate ⭐️, subscribe and share

Dora Cano, líder de la División Pharmaceuticals en Bayer México desde Abril de 2022

Nick talks to Dr. David Cohen, a professor at the UCLA Luskin School of Public Affairs. His research looks at psychoactive drugs (prescribed, licit, and illicit) and their desirable and undesirable effects as socio-cultural phenomena “constructed” through language, policy, attitudes, and social interactions. They discuss: prescription psychiatric drugs, including SSRIs, benzodiazepines and stimulants (e.g. Adderall); the history of how some of the most widely prescribed psychiatric drugs came to be so popular; how pharmaceutical companies go about marketing these drugs and the conditions they aim to treat to both physicians and the public; the quality of the evidence supporting their use; what we are learning about the potential for dependency, long-term health effects, and actual level of benefit that comes from chronic psychiatric drug use; why many psychiatric drugs are increasingly prescribed in combination; and more.Support M&M:Sign up for the weekly Mind & Matter newsletter[https://mindandmatter.substack.com/?sort=top]The Amino Co., shop science-back amino acids supplements. Use code ‘MIND' to save 30%.[aminoco.com/MIND]Follow Nick's work through Linktree:[https://linktr.ee/trikomes]Organize your digital highlights & notes w/ Readwise (2 months free w/ sub)[https://readwise.io/nickjikomes/]Learn more about our podcast sponsor, Dosist[https://dosist.com]Support the show

New authorization for intradermal administration of monkeypox vaccine; a new approval for endometriosis pain; Amazon is among the companies to receive an FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.  

Jenny gives us an update on how trying pharmaceutical medications have affected and helped her on her journey to feeling her best. Even in our careers and our passions, we need to give ourselves a break to recenter and refocus, which has many benefits - one of those being that we find new opportunities within our career, as well as new gifts and new ways to offer what we do. Stay tuned! Want a complimentary FREE 30 MINUTE COACHING SESSION with Jenny?Leave a 5-star iTunes review for Shed the Shame, screenshot it and send it to jwhitens@gmail.com to schedule your FREE session! Find me on Social Media: Facebook - Jenny Whitens Instagram - @jenwhitens // @shedtheshamepodcastTwitter - @jenwhitens Interested in what services Jenny has to offer?Message Jenny on Instagram or Facebook for more info or schedule a complimentary discovery call HERE. 

A neurostimulation device has been cleared for post-C-section pain; a new plaque psoriasis treatment; the FDA address the contrast agent shortage; Lucentis biosimilar treatment is approved; and the recall for an over-the-counter laxative is expanded.

Happy Tuesday from The Stew Peters Show! We are bringing you an amazing new episode following the RELEASE of our new documentary “These Little Ones”! Dr. Peter Breggin was a Professor at Harvard University. He is known as “The Conscience of Psychiatry”, & has done some fantastic works for the stopping of Eugenical programs that were GOVERNMENT FUNDED, & for exposing CPS and their corrupt ways. He joins to talk about the Pharmaceuticals administered to foster children, and how these drugs are EXTREMELY dangerous to children! Diego Rodriguez is the grandfather of baby Cyrus who was kidnapped by CPS in an effort to traffic & sell him into the foster system. Because of all of your hard work, Cyrus was reunited with his family! Diego joins to talk about baby Cyrus, as well as the release of These Little Ones! Greg Phillips joins to shine a light on the election fraud that STOLE President Trump's rightful seat in the Oval Office, and to take action on the illegal activity that occurred in the ballot booths across ALL 50 states. Brandi Brassel from Warrior Bride Ministries is BACK on the show to talk in depth about the Satanic Ritual Abuse that thousands of children undergo each year, and how children are forced into trafficking other children for sacrifices. Watch this new show NOW at StewPeters.com! Visit our friends at Goldco! Call 855-706-GOLD or visit http://goldco.com/SP Prepare your family for famine and shortages by purchasing food through: https://heavensharvest.com Check out http://nootopia.com/StewPeters for help increasing your mental & physical strength to battle the deep-state's KRYPTONITE plot against Americans! Get Dr. Zelenko's Anti-Shedding Treatment, NOW AVAILABLE FOR KIDS: http://zStackProtocol.com CACOA is super good, it's a super food, and it's super based! Buy it now: https://shop.earthechofoods.com/stew Go Ad-Free, Get Exclusive Content, Become a Premium user: https://redvoicemedia.com/premium Follow Stew on Gab: https://gab.com/RealStewPeters See all of Stew's content at https://StewPeters.com Watch full episodes here: https://redvoicemedia.net/stew-full-shows Check out Stew's store: http://StewPeters.shop Support our efforts to keep truth alive: https://www.redvoicemedia.com/support-red-voice-media/

As studies begin to show that obesity medications may save lives, will governments and insurances begin to consider them preventative primary care? And how might this create opportunity in pharmaceuticals? Head of European Pharmaceuticals Mark Purcell and Head of U.S. Pharmaceuticals Terence Flynn discuss.-----Transcript-----Mark Purcell: Welcome to Thoughts on the Market. I'm Mark Purcell, Head of Morgan Stanley's European Pharmaceuticals Team. Terence Flynn: And I'm Terence Flynn, Head of the U.S. Pharmaceuticals Team. Mark Purcell: And on this special episode of Thoughts on the Market, we'll be talking about the global obesity challenge and our outlook for the next decade. It's Tuesday, August the 2nd, and it's 1 p.m. in London. Terence Flynn: And 8 a.m. in New York. Terence Flynn: So Mark, more than 650 million people worldwide are living with obesity as we speak. The personal, social and economic costs from obesity are huge. The World Health Organization estimates that obesity is responsible for 5% of all global deaths, which impacts global GDP by around 3%. Obesity is linked to over 200 health complications from osteoarthritis, to kidney disease, to early loss of vision. So tackling the obesity epidemic would impact directly or indirectly multiple sectors of the economy. Lots to talk about today, but let's start with one of the key questions here: why are we talking about all this now? Are we at an inflection point? And is the obesity narrative changing? Mark Purcell: Yeah Terence look, there's a category of medicine called GLP-1's which have been used to treat diabetes for over a decade. GLP-1 is an appetite suppressing hormone. It works on GLP-1 receptors, you could think of these as hunger receptors, and it helps to regulate how much food our bodies feel they need to consume. Therefore, these GLP-1 medicines could become an important weapon in the fight against obesity. The latest GLP-1 medicines can help individuals who are obese lose 15 to 20% of their body weight. That is equivalent to 45 to 60% of the excess weight these individuals carry in the form of fat which accumulates around the waist and important organs in our bodies such as the liver. There is a landmark obesity study called SELECT, which has been designed to answer the following key question: does weight management save lives? An interim analysis of this SELECT study is anticipated in the next two months, and our work suggests that GLP-1 medicines could deliver a 27% reduction in the risk of heart attacks, strokes and cardiovascular deaths. We believe that governments and insurance companies will broaden the reimbursement of GLP-1 medicines in obesity if they are proven to save lives. This comes at a time when new GLP-1 medicines are becoming available with increasing levels of effectiveness. It's an exciting time in the war against obesity, and we wanted to understand the implications of the SELECT study before it reads out. Terence Flynn: So, our collaborative work suggests that obesity may be the new hypertension. What exactly do we mean by that, Mark? How do we size the global opportunity and what's the timeline here? Mark Purcell: Back in the 1960s and 1970s, hypertension was seen as a lifestyle disease caused by stress and old age. Over time, it was shown that high blood pressure could be treated, and in doing so, doctors could prevent heart attacks and save lives. A new wave of medicines were introduced to the market in the mid 1980s to treat individuals with high blood pressure and doctors found the most effective way to treat high blood pressure was to use combinations of these medicines. By the end of the 1990's, the hypertension market reached $30 billion in sales, that's equivalent to over $15 billion today adjusting for inflation. Obesity is seen by many as a lifestyle disease caused by a lack of self-control when it comes to eating too much. However, obesity is now classified as a preventable chronic disease by medical associations, just like hypertension. Specialists in the obesity field now recognize that our bodies have evolved over hundreds of thousands of years to put on weight, to survive times where there is a lack of food available and a key way to fight obesity is to reset the balance of how much food our bodies think they need. With the availability of new, effective obesity medicines, we believe that obesity is on the cusp of moving into mainstream primary care management. And the obesity market is where the treatment of high blood pressure was in the mid to late 1980s. We built a detailed obesity model focusing on the key bottlenecks, patient activation, physicians engagement and payer recognition. And we believe that the obesity global sales could exceed $50 billion by the end of this decade. Terence Flynn: So Mark, what are the catalysts aligning to unlock the potential of this $50 billion obesity opportunity? Mark Purcell: We believe there are full catalysts which should begin to unlock this opportunity over the next six months. Firstly, the SELECT study, which we talked about. It could be stopped early in the next two months if GOP P1 medicines are shown overwhelmingly to save lives by reducing excess weight. Secondly, the demand for GLP-1 medicines to treat obesity was underappreciated by the pharmaceutical industry. But through the second half of this year, GLP-1 medicines, supply constraints will be addressed and we'll be able to appreciate the underlying patient demand for these important medicines. Thirdly, analysis shows that social media is already creating a recursive cycle of education, word of mouth and heightened demand for these weight loss medicines. Lastly, diabetes treatment guidelines are actively evolving to recognize important comorbidities, and we expect a greater emphasis on weight treatment goals by the end of this year. Terence Flynn: Mark, you mentioned some bottlenecks with respect to the obesity challenge. One of those was patient activation. What's the story there and how does social media play into it? Mark Purcell: Yes, great question Terence, look it's estimated that less than 10% of individuals suffering from obesity are diagnosed and actively managed by doctors. And that compares to 80 to 90% of individuals who suffer from high blood pressure, or diabetes, or high levels of cholesterol. Once patients come forward to see their doctors, 40% of them are treated with an anti-obesity medicine. And as more effective medicines become available, we just think this percentage is going to rise. Lastly, studies designed to answer the question, what benefit does 15 to 20% weight loss deliver in terms of reducing the risk of high blood pressure, diabetes, kidney disease and cardiovascular disease? Will help activate governments and insurance companies to reimburse obesity medicines. But it all starts with individuals suffering from obesity coming forward and seeking help, and this is where we expect social media to play a really important key role. Terence Flynn: To a layperson, there's significant overlap between diabetes and obesity. How do we conceptualize the obesity challenge vis a vis diabetes, Mark? Mark Purcell: Terence, you're absolutely right. There is significant overlap between diabetes and obesity and it makes it difficult and complicated to model. It's estimated that between 80 to 85% of diabetics are overweight. It's estimated that 35% of diabetics are obese and around 10% of diabetics are severely obese. GLP-1 medicines have been used to treat diabetes for over a decade, not only being extremely effective in lowering blood sugar, but also in reducing the risk of cardiovascular events like heart attacks and removing excess body weight, which is being recognized as increasingly important. This triple whammy of benefit means that the use of GLP-1 medicines is increasing rapidly, and sales in diabetes are expected to reach over $20 billion this year, compared to just over $2 billion in obesity. By the end of the decade our work suggests that the use of GLP-1 based medicines in obesity could exceed the use in diabetes by up to 50%. Terence Flynn: Mark, thanks for taking the time to talk. Mark Purcell: Great speaking with you again, Terrence. Terence Flynn: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review on Apple Podcasts and share the podcast with a friend or colleague today.

Learn how to own the power of your multitudes, act on and embracing your ambition, and find your North Star to guide your decisions.THIS WEEK'S TOPIC:If you're a fan of books, or of reading in general, you've probably heard of Hitha Palepu. Palepu's new book, "We're Speaking: The Life Lessons of Kamala Harris" encourages everyone to find their own “north star” and celebrate their multitudes.We are honored and excited to invite Hitha into our community of women working with passion and purpose.THIS WEEK'S GUEST:Hitha Palepu is a woman of multitudes—a feminist, a lifelong politics enthusiast, a daughter of immigrants, and a mother raising feminist sons. These multitudes spill into her multi-hyphenated career as an entrepreneur, investor, writer, and speaker.Hitha's passion for the news and politics is captured in #5SmartReads, a Webby-honored social series that shares 5 must-read articles every day to keep her community informed without being overwhelmed. Hitha's longtime blog, Hitha On The Go, established her as an authority on lifestyle topics and gave way to her book and collaborations with leading brands such as Headspace, Google, and Northwestern Mutual. Her book, How To Pack, was published by Clarkson Potter in 2017.As CEO of Rhoshan Pharmaceuticals, Hitha oversees financing, partnerships, and strategy for the company. Hithan also puts her money where her values are through early stage investing. A partner in Adama Ventures (her family office), she has invested in innovative companies primarily founded by women and focused on women (MM.LaFleur, Girls' Night In, Brightland, and Heymama among them). She is a sought-after speaker on politics & the news, investing, entrepreneurship, work-life juggle, and motherhood.Hitha has spoken at The Riveter Summit, Fohr, Global Brands Group and was selected to speak at SXSW 2020. She is represented by AllRaise's Visionary Voices speakers bureau.In her most recent book called We're Speaking: The Life Lessons of Kamala Harris: How to Use Your Voice, Be Assertive, and Own Your Story, she connects illuminating stories from Harris' unique biography with tactical advice on the importance of being assertive and true to yourself in your personal life and work alike.Support the show

Guest Michael Sassano, CEO of Somai Pharmaceuticals, joins us from Lisbon Spain to discuss the ever changing landscape of the global cannabis marketplace. Michael's experience as a developer and banker in the United States and Europe provides him with a unique set for navigating international rules and regulations for the global medical cannabis industry. 

Ancient cultures all over the world used the pulse as a diagnostic tool. And eventually, we figured out how to measure blood pressure, and hypertension came to be viewed as a disease. Research: Booth, Jeremy. “A Short History of Blood Pressure Measurement.” Proceedings of the Royal Society of Medicine. Vol. 70. Nov. 1977. https://journals.sagepub.com/doi/pdf/10.1177/003591577707001112 Elias, Merrill F. and Amanda L. Goodell. “Setting the record straight for two heroes in hypertension: John J. Hay and Paul Dudley White.” Journal of Clinical Hypertension. 9/21/2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030549/#jch13650-bib-0004 Greene, Jeremy A. “Releasing the Flood Waters: Diruil and the Reshaping of Hypertension.” Bulletin of the History of Medicine, Vol. 79, No. 4, Winter 2005. https://doi.org/10.1353/bhm.2005.0153 Harold, John Gordon. “Harold on History | Historical Perspectives on Hypertension.” American College of Cardiology. 11/20/2017. https://www.acc.org/latest-in-cardiology/articles/2017/11/14/14/42/harold-on-history-historical-perspectives-on-hypertension Hay, John. “The Significance of a Raised Blood Pressure.” British Medical Journal. 7/11/1931. Johnson, Richard J. et al. “The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics.” Renal Physiology. 1/2/2015. https://doi.org/10.1152/ajprenal.00503.2014 Kotchen, Theodore A. “Historical Trends and Milestones in Hypertension Research: A Model of the Process of Translational Research.” Hypertension. Vol. 58, 2011.  https://doi.org/10.1161/HYPERTENSIONAHA.111.177766 Labos, Christopher. “The Current Hypertension Controversy: There is None..” McGill. 2/8/2018. https://www.mcgill.ca/oss/article/general-science/current-hypertension-controversy-there-none Lüscher, Thomas F. “High blood pressure: new frontiers of an old risk factor.” European Heart Journal (2017) 38, 2791–2794. doi:10.1093/eurheartj/ehx544 Moser, Marvin. “Historical Perspectives on the Management of Hypertension.” Journal of Clinical Hypertension. 5/22/2007. https://doi.org/10.1111/j.1524-6175.2006.05836.x Postel-Vinay, Nicolas, editor. “A Century of Arterial Hypertension 1896-1996.” Wiley. 1996. Saklayen, Mohammad G. and Neeraj V. Deshpande. “Timeline of History of Hypertension Treatment.” Frontiers in Cardiovascular Medicine. 2/23/2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763852/ See omnystudio.com/listener for privacy information.